On April 30, 2026, medical technology company EDAP TMS announced significant progress in enhancing their market presence. They released groundbreaking results from the HIFI-2 study, which provided strong support for the effectiveness of their Focal One ® Robotic HIFU system in treating radiorecurrent prostate cancer. This data is expected to solidify EDAP TMS's position in the market as a leader in innovative medical solutions.